
Faculty, Staff and Student Publications
Publication Date
12-1-2023
Journal
Current Opinion in Pharmacology
Abstract
Translating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT2) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT2 receptor antagonists evoked pain relief in rodent models of neuropathic pain. EMA401 was selected as the drug candidate based upon its suitable preclinical toxicity and safety profile and good pharmacokinetics. Herein, we provide an overview of the discovery, preclinical and clinical development of EMA401, for the alleviation of peripheral neuropathic pain.
Keywords
Humans, Receptor, Angiotensin, Type 2, Angiotensin II Type 2 Receptor Blockers, Neuralgia, Benzhydryl Compounds
DOI
10.1016/j.coph.2023.102415
PMID
38041933
PMCID
PMC11789660
PubMedCentral® Posted Date
2-3-2025
PubMedCentral® Full Text Version
Author MSS
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons